Compare DexCom, Inc. (DXCM) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Ryanair Holdings plc — how do they compare? DexCom, Inc. trades at $78.49 (market cap $28.06B), while Ryanair Holdings plc trades at $66.04 (market cap $31.83B). The key difference: DexCom, Inc. and Ryanair Holdings plc are close in size by market cap, and Ryanair Holdings plc pays a 1.48% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | RYAAY | |
|---|---|---|
Market Cap | $28.06B | $31.83B |
Sector | Health | Industrials |
52-Week High | $89.53 | $73.82 |
52-Week Low | $54.84 | $53.24 |
Enterprise Value | $27.03B | $29.49B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
RYAAY trades at $65.97, up 2.61% today, with a bullish technical signal from moving averages. The company shows strong profitability with a 13.98% net margin and 25.37% ROE, supported by consistent traffic growth and a debt-free balance sheet. Recent news highlights operational incidents but also positive developments like CEO contract extension and improved family seating policies.
Outlook remains positive with analyst consensus at 62.5% buy ratings. Key opportunities include fuel cost advantages and market share gains, while risks involve regulatory scrutiny and fuel price volatility. The stock's valuation at P/E 14.32 appears reasonable given earnings growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
